Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Pleco Therapeutics","sponsor":"Oost NL","pharmaFlowCategory":"D","amount":"$17.4 million","upfrontCash":"Undisclosed","newsHeadline":"Pleco Therapeutics Announces Final Close of its Series A Financing Raising \u20ac17.3m to Progress its Novel Plecoid\u2122 Product in Acute Myeloid Leukaemia to Regulatory Filing in USA and EU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Pleco Therapeutics","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Pleco Therapeutics

    Menu

    Pleco Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Pleco Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)

              Details:

              PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity. It is under clinical development for the treatment of cute Myeloid Leukaemia (AML).

              Lead Product(s): PTX-252

              Therapeutic Area: Oncology Product Name: PTX-252

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Recipient: Hyloris Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pleco Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pleco Therapeutics Announces Final Close of its Series A Financing Raising €17.3m to Progress its Novel Plecoid™ Product in Acute Myeloid Leukaemia to Regulatory Filing...

              Details:

              The funds will be used to complete development and commercialise the Company’s novel lead Plecoid™ Product, PTX-061, to improve the effectiveness of chemotherapy in patients with Acute Myeloid Leukaemia (AML).

              Lead Product(s): PTX-061

              Therapeutic Area: Oncology Product Name: PTX-061

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oost NL

              Deal Size: $17.4 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing September 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY